中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

文献类型：期刊论文

作者Zhou, Jianxing1,2; Zheng, You1,2; Xu, Baohua1,2; Long, Songjun3; Zhu, Li-e1; Liu, Yunhui1; Li, Chengliang4; Zhang, Yifan5; Liu, Maobai1; Wu, Xuemei1,2
刊名BMC MEDICINE
出版日期2024-02-14
卷号22期号:1页码:13
ISSN号1741-7015
关键词GLP-1RAs Suicidal or self-injurious behaviors Pharmacovigilance FAERS database Type 2 diabetes Obesity
DOI10.1186/s12916-024-03274-6
通讯作者Liu, Maobai(liumb0591@fjmu.edu.cn) ; Wu, Xuemei(wuxuemei@fjmu.edu.cn)
英文摘要BackgroundEstablishing whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is crucial for public safety. This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database.MethodsA disproportionality analysis was conducted using post-marketing data from the FAERS repository (2018 Q1 to 2022 Q4). SSIB cases associated with GLP-1RAs were identified and analyzed through disproportionality analysis using the information component. The parametric distribution with a goodness-of-fit test was employed to analyze the time-to-onset, and the omega shrinkage was used to evaluate the potential effect of co-medication on the occurrence of SSIBs.ResultsIn total, 204 cases of SSIBs associated with GLP-1RAs, including semaglutide, liraglutide, dulaglutide, exenatide, and albiglutide, were identified in the FAERS database. Time-of-onset analysis revealed no consistent mechanism for the latency of SSIBs in patients receiving GLP-1RAs. The disproportionality analysis did not indicate an association between GLP-1RAs and SSIBs. Co-medication analysis revealed 81 cases with antidepressants, antipsychotics, and benzodiazepines, which may be proxies of mental health comorbidities.ConclusionsWe found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs. Clinicians need to maintain heightened vigilance on patients premedicated with neuropsychotropic drugs. This contributes to the greater acceptance of GLP-1RAs in patients with type 2 diabetes mellitus or obesity. center dot To determine whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs).center dot Is there a direct association between GLP-1RAs and SSIBs? No evidence reasonably suggests an association between GLP-1RAs and SSIBs based on clinical characteristics, time-onset, disproportionality, and co-medication analysis.center dot Clinicians should pay more attention to the psychiatric status of patients with a history of neuropsychotropic drugs, and more comprehensive monitoring is needed to consider their susceptibility to SSIBs carefully.
WOS关键词OBESITY ; ADULTS ; SEMAGLUTIDE ; OVERWEIGHT
WOS研究方向General & Internal Medicine
语种英语
出版者BMC
WOS记录号WOS:001162662000004
源URL[http://119.78.100.183/handle/2S10ELR8/309575]  
专题中国科学院上海药物研究所
通讯作者Liu, Maobai; Wu, Xuemei
作者单位1.Fujian Med Univ, Union Hosp, Dept Pharm, Fuzhou, Fujian, Peoples R China
2.Fujian Med Univ, Sch Pharm, Fuzhou, Fujian, Peoples R China
3.Fujian Med Univ, Sch Med Imaging, Fuzhou, Fujian, Peoples R China
4.Shanghai Elect Power Hosp, Dept Resp, Shanghai, Peoples R China
5.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China
推荐引用方式
GB/T 7714		 Zhou, Jianxing,Zheng, You,Xu, Baohua,et al. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database[J]. BMC MEDICINE,2024,22(1):13.
APA Zhou, Jianxing.,Zheng, You.,Xu, Baohua.,Long, Songjun.,Zhu, Li-e.,...&Wu, Xuemei.(2024).Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.BMC MEDICINE,22(1),13.
MLA Zhou, Jianxing,et al."Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database".BMC MEDICINE 22.1(2024):13.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。